澳大利亚生物制剂风险管理计划系统评价
本研究对2009-2024年澳大利亚公共评估报告中15种用于炎症性关节病、炎症性肠病和炎症性皮肤病的生物制剂风险管理计划进行描述性审查,提取并量化安全关注(重要已识别风险、重要潜在风险和缺失信息)。结果显示246项安全关注中,缺失信息占32.5%,儿童和青少年是最常见缺失信息人群(60%),仅33%的药品有具体提案解决缺失信息。
要点
- 15种生物制剂共列出246项安全关注,缺失信息占32.5%。
- 60%的药品将儿童和青少年列为最常见缺失信息人群。
- 仅33%的药品有具体提案或方案解决缺失信息。
核心结论
- 常用生物制剂上市后风险管理计划存在重要缺口,部分药品虽有长期市场历史,安全关注仍未解决。
- 建议定期监测和批判性审查风险管理计划,以优先开展上市后研究并解决未解决的安全关注。
研究设计与样本
- 对2009-2024年澳大利亚公共评估报告中15种生物制剂的风险管理计划进行描述性审查。
- 15种生物制剂被批准并普遍资助用于炎症性关节病、炎症性肠病和炎症性皮肤病。
主要发现
- 共列出246项安全关注:85项重要已识别风险(34.6%)、81项重要潜在风险(32.9%)和80项缺失信息(32.5%)。
- 9种药品(60%)将儿童和青少年列为最常见缺失信息人群,8种(53%)列孕妇,7种(47%)列肝肾功能损害者。
- 在列出缺失信息的药品中,10种(77%)提出了额外药物警戒活动,仅5种(33%)有具体提案或方案解决缺失信息。
临床怎么用
- 临床药师应关注生物制剂在儿童、孕妇及肝肾功能损害者中的缺失信息,加强用药监测。
- 针对缺失信息人群,可参考风险管理计划中提出的额外药物警戒活动开展主动监测。
局限性
- 本研究仅纳入澳大利亚公共评估报告中15种生物制剂,结果可能不适用于其他生物制剂或监管环境。
- 研究为描述性审查,未评估风险管理计划的实际执行效果或临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Risk management plans (RMPs) are a critical element of pharmacovigilance. However, few studies have examined the quality and type of information included in RMPs, and none has examined the RMPs in the Australian medicines regulatory context. OBJECTIVES: This study aims to characterise safety concerns, particularly missing information listed in the current Australian RMPs for commonly used biologic medicines, and identify additional pharmacovigilance and risk minimisation activities proposed to address identified gaps. METHODS: A descriptive review of RMPs included in the Australian Public Assessment Reports (2009-2024) was performed for 15 biologic medicines approved for use and universally funded in Australia for inflammatory arthropathies, inflammatory bowel diseases and inflammatory skin conditions. We extracted and quantified safety concerns (important identified risks, important potential risks and missing information) from the latest Australian Public Assessment Reports, and further categorised missing information by specific populations and conditions. We then qualitatively described the additional activities proposed. RESULTS: There were 246 safety concerns listed for the 15 medicines of interest: 85 important identified risks (34.6%), 81 important potential risks (32.9%) and 80 instances of missing information (32.5%). More than half (n = 9, 60%) of the reviewed medicines listed children and adolescents as the most common populations with missing information. Pregnant women (n = 8, 53%) and those with hepatic and renal impairment (n = 7, 47%) were also commonly listed as having missing information. Additional pharmacovigilance activities were proposed for two thirds of the medicines (n = 10, 77%) where missing information was listed. Only one third of the reviewed medicines (n = 5, 33%) had specific proposals or protocols listed in the current Australian Public Assessment Reports to address missing information. CONCLUSIONS: Our study identified important gaps in RMPs for commonly used biologic medicines at the post-market phase. Despite some medicines having an extensive market history, these safety concerns remain unaddressed. Regular monitoring and critical review of RMPs are recommended to prioritise post-market studies and address outstanding safety concerns.
引用
- Ho JN, Hillen JB, Daniels B, et al. Systematic Evaluation of Australian Risk Management Plans for Biologic Medicines. Drug Saf. 2025. PMID: 40448798. doi:10.1007/s40264-025-01557-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。